Researchers have identified hundreds of promising targets for existing drugs or potential new cancer drugs. The findings relied heavily on proteogenomic data from more than 1,000 tumors representing 10 types of cancer released last year by NCI's CPTAC program.
Trial participants who stopped imatinib had a more rapid worsening of disease, a shorter time until resistance, and did not live as long as participants who continued the therapy uninterrupted.
A new study may provide important new insights into breast cancer metastasis. Blood vessels within tumors release a molecule that draws sensory nerves closer to the tumors, the study shows. This close proximity turns on genes in the cancer cells that drive metastasis.
Osteonecrosis of the jaw was thought to be a rare side effect of drugs like denosumab (Xgeva) that lessen bone problems when cancer has spread to the bone. But a new study has found that the painful side effect is more common than once thought.
DNA fragments from retroviruses that are millions of years old appear to be active in a variety of cancers, a new study found. One virus-derived DNA fragment in particular, known as LTR10, turns on cancer-related genes in multiple types of cancer.